Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT) (http://www.pvct.com),
a development-stage oncology and dermatology biopharmaceutical company
(“Provectus”), announced today that Sanjiv S. Agarwala, MD, of St.
Luke's University Hospital and Professor of Medicine at Temple
University will present data on its investigational new drug PV-10 for
the treatment of melanoma at the 11th International Congress
of the Society for Melanoma Research in Zurich, Switzerland.
Dr. Agarwala’s presentation will take place as a Satellite Symposium
sponsored by Amgen and is titled “Oncolytic immunotherapy – engaging the
immune system to target melanoma.”
Dr. Agarwala said, “I am very happy to be presenting our IL PV-10 data
at the 2014 International Congress of the SMR. The Society’s stated
mission is to increase communication among melanoma researchers. I agree
that the exchange of knowledge and ideas is critical for the field, and
my participation at the Congress is just one way in which we at St.
Luke’s are working to improve the information flow among researchers,
physicians and patients.”
Dr. Craig Dees, PhD, CEO of Provectus, said, "Provectus is pleased that
Dr. Agarwala is extending his travel schedule to share his work with IL
PV-10 at the 2014 Congress of the SMR. We are confident that the
enhanced exposure he is giving the melanoma community to data on PV-10
can result in wider awareness of the unique features of the agent.”
PV-10, a 10% solution of Rose Bengal that is currently being examined as
a novel cancer therapeutic, is designed for injection into solid tumors,
minimizing potential for systemic side effects.
About the SMR
The SMR’s principal goal is bringing together members who vary widely in
their professions—from basic researchers to translational researchers to
clinicians— but share an abiding devotion to improving the lives of
those suffering from melanoma through research.
In coming years, with the incorporation of new technologies into
experimental and clinical research, we expect rapid advances in
cutaneous melanoma prevention, diagnosis and therapy. To bring new
technology-based discoveries from bench to bedside and back, we will
need to attain a far greater level of cooperation between labs and
clinics. In addition, we expect to develop specific inhibitors for
metastatic melanoma, rendering it in the next few years a treatable
disease. For further information, visit http://www.societymelanomaresearch.org/
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., specializes in developing oncology
and dermatology therapies. PV-10, its novel investigational drug for
cancer, is designed for injection into solid tumors (intralesional
administration), thereby reducing potential for systemic side effects.
Its oncology focus is on melanoma, breast cancer and cancers of the
liver. The Company has received orphan drug designations from the FDA
for its melanoma and hepatocellular carcinoma indications. PH-10, its
topical investigational drug for dermatology, is undergoing clinical
testing for psoriasis and atopic dermatitis. Provectus has completed
phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of
PH-10 as a topical treatment for atopic dermatitis and psoriasis.
Information about these and the Company’s other clinical trials can be
found at the NIH registry, www.clinicaltrials.gov.
For additional information about Provectus, please visit the Company’s
website at www.pvct.com
or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains “forward-looking
statements” as defined under U.S. federal securities laws. These
statements reflect management’s current knowledge, assumptions, beliefs,
estimates, and expectations and express management’s current views of
future performance, results, and trends and may be identified by their
use of terms such as “anticipate,” “believe,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” and
other similar terms. Forward-looking statements are subject to a number
of risks and uncertainties that could cause our actual results to
materially differ from those described in the forward-looking
statements. Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking statements
include those discussed in our filings with the Securities and Exchange
Commission (including those described in Item 1A of our Annual Report on
Form 10-K for the year ended December 31, 2013, and in our Quarterly
Reports on Form 10-Q for the quarters ended March 31, 2014, and June 30,
2014), and the following:
|
|
•
|
|
our determination, based on guidance from the FDA, whether to
proceed with or without a partner with a phase 3 trial of PV-10 to
treat locally advanced cutaneous melanoma and the costs associated
with such a trial if it is necessary;
|
|
|
•
|
|
our determination whether to license PV-10, our melanoma drug
product candidate, and other solid tumors such as liver cancer, if
such licensure is appropriate considering the timing and structure
of such a license, or to commercialize PV-10 on our own to treat
melanoma and other solid tumors such as liver cancer;
|
|
|
•
|
|
our ability to license our dermatology drug product candidate,
PH-10, on the basis of our phase 2 atopic dermatitis and psoriasis
results, which are in the process of being further developed in
conjunction with mechanism of action studies; and
|
|
|
•
|
|
our ability to raise additional capital if we determine to
commercialize PV-10 and/or PH-10 on our own, although our
expectation is to be acquired by a prospective pharmaceutical or
biotech concern prior to commercialization.
|
Copyright Business Wire 2014